1. Home
  2. IVVD vs PMO Comparison

IVVD vs PMO Comparison

Compare IVVD & PMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IVVD
  • PMO
  • Stock Information
  • Founded
  • IVVD 2020
  • PMO 1993
  • Country
  • IVVD United States
  • PMO United States
  • Employees
  • IVVD N/A
  • PMO N/A
  • Industry
  • IVVD Biotechnology: Pharmaceutical Preparations
  • PMO Finance Companies
  • Sector
  • IVVD Health Care
  • PMO Finance
  • Exchange
  • IVVD Nasdaq
  • PMO Nasdaq
  • Market Cap
  • IVVD 351.6M
  • PMO 291.4M
  • IPO Year
  • IVVD 2021
  • PMO N/A
  • Fundamental
  • Price
  • IVVD $1.61
  • PMO $10.36
  • Analyst Decision
  • IVVD Strong Buy
  • PMO
  • Analyst Count
  • IVVD 5
  • PMO 0
  • Target Price
  • IVVD $6.11
  • PMO N/A
  • AVG Volume (30 Days)
  • IVVD 6.2M
  • PMO 99.0K
  • Earning Date
  • IVVD 11-07-2025
  • PMO 01-01-0001
  • Dividend Yield
  • IVVD N/A
  • PMO 4.10%
  • EPS Growth
  • IVVD N/A
  • PMO N/A
  • EPS
  • IVVD N/A
  • PMO 0.42
  • Revenue
  • IVVD $46,210,000.00
  • PMO N/A
  • Revenue This Year
  • IVVD $102.11
  • PMO N/A
  • Revenue Next Year
  • IVVD $151.51
  • PMO N/A
  • P/E Ratio
  • IVVD N/A
  • PMO $24.38
  • Revenue Growth
  • IVVD 1941.08
  • PMO N/A
  • 52 Week Low
  • IVVD $0.35
  • PMO $8.57
  • 52 Week High
  • IVVD $2.74
  • PMO $10.68
  • Technical
  • Relative Strength Index (RSI)
  • IVVD 46.79
  • PMO 53.73
  • Support Level
  • IVVD $1.74
  • PMO $10.30
  • Resistance Level
  • IVVD $2.00
  • PMO $10.42
  • Average True Range (ATR)
  • IVVD 0.24
  • PMO 0.07
  • MACD
  • IVVD -0.06
  • PMO -0.02
  • Stochastic Oscillator
  • IVVD 1.33
  • PMO 27.50

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

About PMO Putnam Municipal Opportunities Trust

Putnam Municipal Opportunities Trust is a non-diversified closed-end management investment company. It seeks to provide as high a level of current income free from federal income tax as Putnam Management believes is consistent with the preservation of capital. The fund invests in healthcare, utilities, transportation, tax bonds, local debt, state debt, and education.

Share on Social Networks: